RCM
RLMD icon

RA Capital Management’s Relmada Therapeutics RLMD Stock Holding History

RA Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,947,369
Closed -$20.5M – 91
2026
Q1 		$20.5M Buy
+2,947,369
New +$13.9M 0.22% 58
2022
Q4 		– Sell
-2,000,000
Closed -$74M – 79
2022
Q3 		$74M Hold
2,000,000
– – 1.58% 18
2022
Q2 		$38M Hold
2,000,000
– – 1.01% 32
2022
Q1 		$54M Hold
2,000,000
– – 1.18% 25
2021
Q4 		$45.1M Buy
+2,000,000
New +$44.5M 0.79% 37
2020
Q4 		– Sell
-781,290
Closed -$29.4M – 86
2020
Q3 		$29.4M Sell
781,290
-70,617
-8% -$2.73M 0.54% 43
2020
Q2 		$38.1M Sell
851,907
-528,081
-38% -$22.3M 0.74% 33
2020
Q1 		$47.1M Buy
1,379,988
+618,322
+81% +$24.9M 1.49% 24
2019
Q4 		$29.7M Buy
+761,666
New +$23.1M 0.9% 24

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RA Capital Management's RLMD Position: Q2 2026 in Review

RA Capital Management sold out of Relmada Therapeutics (RLMD) in Q2 2026, closing a stake of 2,947,369 shares — an estimated $20.5M sold.

RA Capital Management first reported a position in RLMD in Q4 2019 and held it in 9 quarters. The position peaked at $74M in Q3 2022. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • RA Capital Management reported no remaining Relmada Therapeutics position as of Q2 2026 after selling out during the quarter.
  • RA Capital Management sold 2,947,369 Relmada Therapeutics shares in Q2 2026, an estimated $20.5M.
  • RA Capital Management first reported a position in Relmada Therapeutics in Q4 2019 and held it in 9 quarters.
  • RA Capital Management's Relmada Therapeutics position peaked at $74M in Q3 2022.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.